Benchling Builds Digital Data Foundation Powering Sanofi AI-Driven R&D
Benchling, the R&D Cloud powering the biotech industry, today announced that global pharmaceutical company Sanofi is using Benchling across more than 1,500…
Pharmaceuticals, Biotechnology and Life Sciences
Benchling, the R&D Cloud powering the biotech industry, today announced that global pharmaceutical company Sanofi is using Benchling across more than 1,500…
NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases,…
CordenPharma and Certest are partnering up to add ionizable lipids to CordenPharma’s complex LNP formulation services
World Food Safety Day is jointly facilitated
by the Food and Agriculture Organization
of the United Nations (FAO) and the World
Health Organization (WHO), and aims to
draw attention and inspire action to help
prevent, detect and manage foodborne
risks, contributing to food security,
human health, economic prosperity,
agriculture, market access, tourism and
sustainable development.
Bristol Myers Squibb presented results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab)…
The Prange Group and its affiliate Adragos Pharma have successfully acquired the Fresenius Kabi production site in Halden, Norway, a leading sterile pharmaceutical manufacturing facility. This strategic move signifies a significant step forward for both companies, expanding their global footprint and enhancing their capacity for sterile liquid production.
New findings from the VESTIGE trial reveal the effectiveness of Dupixent (dupilumab) in managing uncontrolled moderate-to-severe asthma.
Oxford Cannabinoid Technologies Holdings, the biotech company developing prescription cannabinoid medicines, has appointed Lord Mott OBE as an independent Non-Executive Director, effective immediately.
GSK has appointed Dr Jeannie Lee to the Board of the Company as a Non-Executive Director, who will join the Board on 4 March 2024.
PulseSight Therapeutics SAS, a biotech company, launches with funding from Pureos Bioventures and ND Capital. It aims to validate its innovative delivery platform by advancing drugs for age-related macular diseases.